HIF1A and neoplasm: However, adaptive resistance can be prevented by the use of combination treatment, such as shown in a study by Hartwich et al., where the suppression of HIF1alpha using topotecan potentiated the effects of bevacizumab in neuroblastoma NB1691 cell line, significantly reducing tumour growth compared to either treatment alone [163].